Applied Genetic Technologies (NASDAQ: AGTC) reported Q2 EPS of $0.17, may not compare to the analyst estimate of ($0.19). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $8.76 million.

For earnings history and earnings-related data on Applied Genetic Technologies (AGTC) click here.